On October 28, 2022 Shanghai Fosun Kite reported China’s NMPA has accepted its NDA filing of the company’s CAR-T as a second-line therapy for large B cell lymphoma. One year ago, Yikaida was approved for third-line use in the same disease (Press release, Fosun Kite Biotechnology, OCT 28, 2022, View Source [SID1234622594]). Fosun Kite is a joint venture tasked with bringing Kite’s Yescarta to China. The drug, axicabtagene ciloleucel, is an autologous CD19 CAR T-cell therapy manufactured in China under a Kite license. The new indication will be for adult patients with large B cell lymphoma who did not respond to first-line immunochemo therapy or who relapsed within 12 months.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!